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Summary
We used small molecule screening to discover compounds and mechanisms for overcoming E6 oncogene-mediated drug
resistance. Using high-throughput screening in isogenic cell lines, we identified compounds that potentiate doxorubicin’s
lethality in E6-expressing colon cancer cells. Such compounds included quaternary ammonium salts, protein synthesis
inhibitors, 11-deoxyprostaglandins, and two additional classes of compounds—analogs of 1,3-bis(4-morpholinylmethyl)-
2-imidazolidinethione (a thiourea) and acylated secondary amines that we named indoxins. Indoxins upregulated topoisom-
erase IIa, the target of doxorubicin, thereby increasing doxorubicin lethality. We developed a photolabeling strategy to iden-
tify targets of indoxin and discovered a nuclear actin-related protein complex as a candidate indoxin target.Introduction
The ability of tumor cells to survive treatment with any of nu-
merous unrelated anticancer drugs is known as multidrug re-
sistance (MDR) (Krishna and Mayer, 2000). Specifically, resis-
tance to apoptosis-inducing drugs is one of the hallmarks of
cancer (Hanahan and Weinberg, 2000): most cancer cells
eventually acquire alterations that enable them to evade apo-
ptosis. This ability contributes to the drug-resistant phenotype
found in human cancers (Johnstone et al., 2002). For example,
the tumor suppressor protein p53, which is a central signaling
protein involved in apoptosis, is mutated in more than 50% of
human cancers (Levine, 1997). Most commonly, the TP53
gene is inactivated via mutation (Hainaut et al., 1998; Olivier
et al., 2002). However, amplification of the Murine Double Min-
ute 2 (MDM2) oncogene, which encodes an E3 ubiquitin ligase
that targets p53 for proteasomal degradation, also leads
to loss of p53 protein (Michael and Oren, 2003). In addition, vi-
ral oncoproteins, such as HPV E6, SV40 large T antigen, and
human hepatitis B virus X protein, are capable of interfering
with p53 function, and thereby increasing the resistance of tu-
mor cells to chemotherapeutic agents (Collot-Teixeira et al.,
2004).
HPV type 16 and 18 (HPV16 and HPV18) are the major caus-
ative factors in cervical cancer (Bosch et al., 1995; Schiffman
and Castle, 2003; zur Hausen, 1996). More than 90% of cervical
cancer patients have been infected with these high-risk viruses
that are capable of immortalizing and transforming normalCANCER CELL 9, 133–146, FEBRUARY 2006 ª2006 ELSEVIER INC. DOIhuman cells (Bosch et al., 1995). HPV16 and HPV18 are associ-
ated with high-grade squamous intraepithelial lesions; invasive
cervical carcinomas (Slebos et al., 1995); and anal, peri-anal,
vulvar, and penile cancers (zur Hausen, 2000). Two viral genes,
E6 and E7, are required for HPV16/18-mediated carcinogenesis
(Munger et al., 1989).
The viral protein E6 induces p53 ubiquitination and degrada-
tion by complexing with E6 Associated Protein (E6AP), which is
an E3 ligase (Scheffner et al., 1990, 1993). E6/E6AP-mediated
degradation of p53 allows tumor cells to overcome cell cycle
checkpoint control in DNA-damaged cells, contributing to the
mutagenic and antiapoptotic effects of E6 (zur Hausen, 2000,
2002). E6 also facilitates degradation of the proapoptotic protein
BCL2-antagonist/killer (BAK) (Thomas andBanks, 1998) and ac-
tivates telomerase (Veldman et al., 2001).
HPV-induced malignant growth of cervical cancer depends
upon continuous expression of E6. Although there are no spe-
cific therapies available, various approaches have been used
in attempts to overcome E6-induced resistance to apoptosis.
Antisense inhibition of the E6 oncogene blocks the malignant
phenotype of cervical cancer cells (von Knebel Doeberitz
et al., 1992), and siRNAs targeting the viral E6 oncogene
mRNA effectively kill HPV-positive cancer cells (Butz et al.,
2003). HPV16 E6 protein binding aptamers have been shown
to eliminate HPV16-positive cancer cells by inducing apoptosis
(Butz et al., 2000). While these approaches do lead to death of
E6-expressing cells, they are unlikely to provide effective thera-
peutic agents in the near future.S I G N I F I C A N C E
We have discovered compounds that increase doxorubicin’s lethality in tumor cells that are relatively resistant to doxorubicin. These
compounds can be used to reveal specific mechanisms for overcoming resistance of tumor cells to apoptosis-inducing drugs such as
doxorubicin. To illuminate the mechanisms of action of these compounds, we designed both a pathway-based analysis and improved
affinity probes for protein target identification. In addition, these doxorubicin-enhancing small molecules may be developed into ad-
juvant treatments for doxorubicin-resistant cancers.10.1016/j.ccr.2006.01.012 133
A R T I C L EFigure 1. Differential effect of doxorubicin treatment on RKO and RKO-E6 cells
A: Cell viability assay: RKO and RKO-E6 cells were treated with doxorubicin for 16 hr to evaluate RKO-E6 cell resistance to doxorubicin. The largest differential in
cell survival was observed at 0.50 mg/ml of doxorubicin. The high-throughput screen was performed in the presence of 0.50 mg/ml of doxorubicin. Compounds
that restored doxorubicin-induced killing were further evaluated.
B: Western blot of p53: p53 cellular concentration is lower in the presence of E6 (see RKO and RKO-E6). Treatment with 0.5 mg/ml doxorubicin or camptothecin
for 16 hr caused p53 to accumulate; in RKO-E6 cells, p53 accumulates to a lesser extent, due to E6/E6AP-mediated degradation. The blot was simultaneously
probed with an antibody directed against eIF-4E to control for protein loading.Small molecules, however, aremore easily adaptable for thera-
peutic use than peptide or nucleic acid reagents, but few
examples of small molecules that overcome E6-induced drug
resistance have been described in the literature. The glycolytic
pathway inhibitor 2-deoxyglucose (2-DG) has been reported to
suppress transcriptionofHPV18 in cervical carcinoma cells (Mae-
hama et al., 1998). The antioxidant pyrrolidine-dithiocarbamate
(PDTC) suppresses HPV16 expression in human keratinocytes
by modulating activity of the transcription factor AP-1 (Rosl
et al., 1997). Dithiobisamine-based substances bind to the
HPV16 E6 zinc finger and inhibit its activity (Beerheide et al.,
2000). The histonedeacetylase (HDAC) inhibitors sodiumbutyrate
and trichostatin A induce G1/S phase arrest in HPV18-positive
cervical carcinoma cells, followed by apoptosis, circumventing
E6 antiapoptotic activity (Finzer et al., 2001, 2004). These exam-
ples suggest that it is possible to find small molecules that sup-
press HPV-induced tumorigenicity, although the reported exam-
ples lack specificity. Therefore, we sought to use small molecule
screens (Smukste and Stockwell, 2005; Stockwell, 2000a,
2000b, 2004) to identify novel mechanisms and compounds for
overcoming E6-induced resistance to apoptosis.
Results
In an attempt to identify compounds that overcome E6-induced
drug resistance, we employed a cell-based model, the RKO co-
lon carcinoma cell line (with high levels of p53), and an isogenic
RKO-E6 cell line expressing the E6 oncoprotein. As expected,
RKO-E6 cells have lower levels of p53 and fail to arrest in
G1/S phase after various drug treatments (Slebos et al., 1995).
We found that RKO-E6 cells are 2-fold to 4-fold more resistant
to the anticancer drug doxorubicin compared to RKO cells
(Figure 1). Doxorubicin is a DNA topoisomerase II-based DNA-
damaging agent that induces double-strand DNA breaks, p53
stabilization, and apoptosis. Doxorubicin-treated RKO-E6 cells
have lower levels of p53 than doxorubicin-treated RKO cells134(Figure 1), suggesting that resistance to doxorubicin is caused,
at least in part, by E6-induced degradation of p53. Thus, com-
pounds that overcome E6-induced resistance should restore
doxorubicin’s lethality in RKO-E6 cells. We reasoned that such
compounds might target E6, E6AP, p53, MDM2, or other pro-
teins involved in the cellular response to doxorubicin.
In the primary screen, we identified compounds that inhibited
proliferation of RKO-E6 cells in the presence of a dose of doxo-
rubicin to which they were otherwise resistant. Cell viability was
measured in 384-well format using Alamar Blue (Nociari et al.,
1998), which is a fluorescent dye that detects cellular metabolic
activity and correlates with cellular viability. RKO-E6 cells were
treated with 4 mg/ml of each test compound, corresponding to
10 mM for a compound with a molecular weight of 400, and
0.5 mg/ml (0.9 mM) of doxorubicin for 24 hr. Each compound
was tested in three replicates. We tested compounds in our an-
notated compound library (ACL; 2214 compounds) (Root et al.,
2003); the NINDS library of 1040 compounds (Lunn et al., 2004);
and our TIC library (Kelley et al., 2004), which encompasses
23,685 natural products, natural product analogs, and synthetic
compounds (all tested compound structures and all activity data
are provided in the Supplemental Data available with this article
online). We identified 208 compounds from the TIC library that
caused at least 25% reduction in Alamar Blue fluorescence in
RKO-E6 cells in the presence of 0.5 mg/ml of doxorubicin, and
70 compounds from ACL and NINDS libraries that induced at
least 30% RKO-E6 cell growth inhibition in the presence of
0.5 mg/ml of doxorubicin. We reasoned that among these 278
compounds there should be compounds that are not lethal on
their own but restore sensitivity of RKO-E6 cells to doxorubicin.
To identify such compounds, we performed a secondary
screen in which 272 of the primary hit compounds were tested
in 2-fold dilution series in RKO cells in the absence of doxorubi-
cin and in RKO-E6 cells in the presence of doxorubicin (the pro-
tocol for the screen, the tested compounds, and all activity data
are provided in the Supplemental Data). This screen allowed usCANCER CELL FEBRUARY 2006
A R T I C L EFigure 2. Quaternary ammonium compounds that enhance doxorubicin lethality
A: Structures of quaternary ammonium compounds (QACs) that selectively upregulated doxorubicin’s lethality in RKO-E6 cells. GMS-041F is an analog of ben-
zalkonium chloride that has been reported to inhibit proliferation of several human cancer cell lines (Gastaud et al., 1998).
B: RKO-E6 cells were treated with cetrimonium bromide in the presence of 0.5 mg/ml doxorubicin or camptothecin for 24 hr in 384-well plates. Percent inhibition
of cell proliferation, measured with Alamar Blue, is shown in the graph. The 20% growth inhibition at 0 mg/ml cetrimonium bromide represents the toxicity of
0.5 mg/ml doxorubicin alone or 0.5 mg/ml camptothecin alone in RKO-E6 cells.to eliminate compounds that are equally lethal to RKO cells in
the absence of doxorubicin; such a filter should eliminate com-
pounds that induce cell death via pathways independent of E6
and doxorubicin. We selected 88 compounds for further analy-
sis that exhibited at least 20% greater cell growth inhibition in
RKO-E6 cells in the presence of doxorubicin compared to the le-
thality of these compounds alone in RKO cells.
Compounds that overcome E6-induced doxorubicin resis-
tance might act by upregulating p53. Thus, all 88 compounds
were tested for their ability to upregulate p53 in RKO-E6 cells us-
ingWestern blotting. Only one of the 88 compounds (designated
T86N7) triggered a moderate w50% upregulation of p53
(the structure and activity of this compound are provided in
the Supplemental Data), indicating that most compounds re-
stored doxorubicin lethality without directly inhibiting E6AP or
E6 or even upregulating p53 by other means. This compound,
T86N7, showed inconsistent activity in subsequent viability
tests and showed no selective activity in a number of other can-
cer cell lines and therefore was not investigated further. Overall,
we were surprised to find that overcoming the effect of E6 on
p53 protein levels is difficult using a small molecule screening
approach. However, given that all 88 of these compounds in-
creased the sensitivity of RKO-E6 cells to doxorubicin (modestly
or profoundly), we sought to uncover the basis for their desired
resensitization activity.
To further group the 88 compounds based on their mecha-
nism of action, we developed a pathway-based analysis using
a cotreatment strategy. For these assays, we selected the mi-
crotubule inhibitor podophyllotoxin, the topoisomerase I-based
DNA-damaging agent camptothecin, and doxorubicin itself. The
antimitotic drug podophyllotoxin inhibits tubulin polymerization,
leading to apoptosis, while camptothecin and doxorubicin re-
cruit topoisomerase I and topoisomerase II, respectively, toCANCER CELL FEBRUARY 2006introduce DNA strand breaks, which in return induce apoptosis.
RKO-E6 cells were cotreated with selected compounds
and with podophyllotoxin, camptothecin, or doxorubicin. Com-
pounds that increased sensitivity to all three of these lethal
compounds were assumed to act through general cell death
mechanisms and were eliminated from further consideration.
Compounds that enhanced sensitivity to both camptothecin
and doxorubicin, but not podophyllotoxin, presumably operate
downstream of the DNA damage response. Finally, compounds
that synergized only with doxorubicin were likely to operate at
the level of, or upstream of, topoisomerase II proteins.
For this tertiary screen, we selected the 24 most selective and
active compounds from the secondary screen. Only a few
representative compounds from each structural class of small
molecules were tested. Each of these compounds was tested
in four replicates in RKO and RKO-E6 cell lines alone, and with
doxorubicin or podophyllotoxin (these compounds and activity
data are provided in the Supplemental Data). Compounds that
potentiated podophyllotoxin’s toxicity were eliminated from fur-
ther consideration, while compounds that confirmed their ability
to selectivity increase doxorubicin’s lethality in RKO-E6 and/or
RKO cells were analyzed in more detail.
Below, we describe structurally and functionally related
groups of compounds that emerged from these screens and
candidate mechanisms of action.
Quaternary ammonium compounds
The first class of doxorubicin-enhancing agents comprised qua-
ternary ammonium compounds (QACs), such as cetrimonium
bromide, cetylpyridinium chloride, benzethonium chloride, and
benzalkonium chloride. These compounds selectively increased
doxorubicin’s lethality in RKO-E6 cells but did not synergize with
camptothecin (Figure 2). QACs have been reported to act as135
A R T I C L EFigure 3. Protein synthesis inhibitors enhance doxorubicin lethality
A: Chemical structures of protein synthesis inhibitors that were found to enhance doxorubicin lethality.
B: Effect of cycloheximide on RKO-E6 cells in the presence of 0.5 mg/ml doxorubicin or 0.2 mg/ml podophyllotoxin. RKO-E6 cells were treated in 384-well plates
for 24 hr. Percent inhibition of cell proliferation, measured with Alamar Blue, is shown in the graph.membrane-disrupting agents by solubilizing the cytoplasmic
membrane in bacteria and yeast. The ability of such compounds
to disrupt the cytoplasmic membrane of tumor cells and in-
crease their permeability could facilitate doxorubicin’s uptake
and lethality in RKO-E6 cells.
Benzalkonium salts have effects on a variety of cells (including
T cells); downregulate tumor necrosis factor (TNF) expression;
and are effective bactericidal, fungicidal, and virucidal agents
with pleiotropic (direct and immunologically mediated) inhibitory
activity against pathogens (Patarca and Fletcher, 1995; Patarca
et al., 2000). Although these compounds have been primarily
used as anti-infective agents, an analog of benzalkonium chlo-
ride has been reported to inhibit proliferation of several human
cancer cell lines (Gastaud et al., 1998). These authors proposed
that the ability of quaternary ammonium functional groups to act
as alkylating agents might be responsible for their inhibitory
effect on tumor cells. However, benzethonium chloride and
benzalkonium chloride did not induce apoptosis in RKO-E6
cells in the absence of doxorubicin, casting doubt on this ex-
planation. In addition, these compounds did not induce cell cy-
cle arrest, which is typically caused by DNA alkylating agents,
and did not upregulate p53, p21, or caspase 3, implying a differ-
ent mechanism of activity (data not shown). These compounds
may be fairly benign agents that could be used for overcoming
resistance to doxorubicin.
Protein synthesis inhibitors
Cycloheximide, emetine, and dihydrolycorine potentiated doxo-
rubicin’s lethality in RKO-E6 cells, although at higher concen-
trations they exhibited lethality on their own (Figure 3). Protein
synthesis inhibitors have been reported to sensitize cells to
members of the TNF family (Choi et al., 2004) and to cisplatin
(Budihardjo et al., 2000). Contrary to our observations, however,
there are several reports that cycloheximide antagonizes doxo-
rubicin-induced apoptosis (Bonner and Lawrence, 1989; Furu-
sawa et al., 1995). It is likely that protein synthesis inhibition
has diverse effects, depending on the concentrations used for
treatment and the genetic makeup of the target cells.
Consistent with its reported inhibitory effects on protein syn-
thesis, cycloheximide caused a disappearance of p53 and p21
in RKO-E6 cells, even when cotreated with doxorubicin. On the
other hand, cycloheximide caused increased topoisomerase IIa
levels in RKO-E6 cells. Protein synthesis inhibitors appear,136somewhat unexpectedly, to constitute an effective class of
agents for restoring doxorubicin lethality.
T13F16 is a close analog of emetinewithmodest activity in our
viability studies (Figure 3 and data not shown). However, it ap-
pears to lack potent protein synthesis inhibitor activity and did
not prevent upregulation of p53 and p21 in response to doxoru-
bicin’s treatment. This analogmay have fewer undesired side ef-
fects than the more potent protein synthesis inhibitors.
11-deoxyprostaglandin E1
11-deoxyprostaglandin E1 analogs (e.g., T19I13) were isolated
in the screen. Depending upon the amide functionality, these
compounds exhibited a broad range of activity and selectivity,
while the parent compound 11-deoxyprostaglandin E1 showed
no activity in this screen (Figure 4 and data not shown). T19I13
induced late S/G2 phase arrest in RKO-E6 cells, while no
changes in cell cycle were observed in RKO cells. Upon cotreat-
ment with doxorubicin and T19I13, RKO-E6 cells accumulated
in S/G2 phase, while RKO cells populated G1 and late S/G2
phase. T19I13 selectively increased doxorubicin’s lethality,
while not synergizing with podophyllotoxin or camptothecin.
However, a rapid loss of activity of T19I13 (likely due to loss of
the allylic hydroxyl functionality) in cell culture was observed, im-
peding further testing of this analog series. Thus, although these
prostaglandin analogs have potent activity, their chemical insta-
bility renders them unsuitable for use as probes or drug candi-




its analogs represent an unexplored class of small molecules.
We found that, at low micromolar concentrations, these com-
pounds increased both doxorubicin’s and camptothecin’s le-
thality in RKO and RKO-E6 cells (Figure 5A). T55D7 was studied
in more detail as a prototypical member of this compound class;
it upregulated doxorubicin’s potency in other cell lines: HeLa,
TC32, and A673. However, T55D7 did not increase the micro-
tubule inhibitor podophyllotoxin’s lethality, indicating a DNA
damage-relatedmechanism of action. Only at very high concen-
trations (30–100 mM) did T55D7 and its analogs exhibit doxoru-
bicin-independent lethality (Figure 5A). To investigate whether
T55D7 truly synergizes with doxorubicin, we treated RKO,CANCER CELL FEBRUARY 2006
A R T I C L EFigure 4. 11-deoxyprostaglandin E1 analogs that enhance doxorubicin lethality
RKO cells were treated with 8 mg/ml of each 11-deoxyprostaglandin E1 analog, and RKO-E6 cells were treated with 8 mg/ml of 11-deoxyprostaglandin E1 an-
alog and 0.5 mg/ml of doxorubicin. The percent inhibition of cell proliferation is shown and listed next to each analog. Amide functionalities are colored based
on their activity: active and selective analogs, red; moderately active and selective analogs, green; toxic analogs, black; and inactive analogs, blue.RKO-E6, HeLa, and TC32 cell lines with a combination dosema-
trix of T55D7 and doxorubicin (Figure 5C). The Bliss indepen-
dence model predicts the combined response C for two single
compounds with effects A and B according to the relationship
C = A + B 2 A*B and represents one of the most stringent re-
quirements for synergy (Keith et al., 2005). According to this
model, the excess over predicted Bliss independence repre-
sents the synergistic effect of the combination treatment at a
given pair of concentrations. Based on this analysis, T55D7 ex-
ceeded Bliss independence with doxorubicin at multiple doses;
the most significant potentiation of doxorubicin’s lethality was
found in RKO-E6 cells (Figure 5C and Supplemental Data).
Surprisingly, Western blot analysis of RKO-E6 cells cotreated
with doxorubicin and T55D7 analogs showed no changes in
p53, p21, or MDM2 levels, compared to doxorubicin-treated
cells. T55D7 and its analogs also did not change p53 concentra-
tion in the absence of doxorubicin, implying that the ability of
these compounds to potentiate doxorubicin’s toxicity is not
caused by their ability to induce DNA damage or affect pro-
cesses upstream of 53.
Notably, T55D7 treatment resulted in pronounced S phase ar-
rest in RKO-E6 cells, while virtually no changes in the cell cycle
were observed in RKO cells (Figure 5B).WhenRKO and RKO-E6
cells were cotreated with T55D7 and doxorubicin, we observed
a broadening of the G2 phase and an increase in S phase in
RKO-E6 cells, while RKO cell cycle distribution was similar to
doxorubicin-only treatment. Thus, T55D7 and related analogs
have the ability to enhance the lethality of DNA-damaging
agents in numerous tumor cell lines. These compounds might
be developed into adjuvant therapies for doxorubicin and other
DNA-damaging agents.CANCER CELL FEBRUARY 2006Indoxins
T13M9 and T20D5 are representatives of a group of compounds
that we named indoxins for their ability to increase doxorubicin’s
lethality selectively. These small molecules selectively increased
doxorubicin’s lethality in RKO, RKO-E6, HeLa, and TC32 cells,
while showing no synergy with camptothecin or podophyllo-
toxin. A Bliss independence analysis showed that indoxins
and doxorubicin have synergistic effects in all four cell lines (Fig-
ure 6E and Supplemental Data). This doxorubicin selectivity
implied a topoisomerase II-related mechanism of action. In-
deed, direct upregulation of topoisomerase IIa was detected
in RKO and RKO-E6 cells treated with indoxin A and indoxin B
using Western blotting (Figure 6C). Interestingly, indoxins also
induced S phase arrest in RKO-E6 cells, while not affecting the
cell cycle distribution of RKO or HeLa cells (Figure 6D). Topo-
isomerase IIa is upregulated during S phase and G2/M phases.
However, since increased topoisomerase IIa levels were ob-
served in RKO and RKO-E6 cells, but S phase arrest was only
seen in RKO-E6 cells, these two events seems to be indepen-
dent in this assay system.
A series of indoxin analogs were synthesized to assess func-
tionalities necessary for their activity. Structure-activity analysis
of indoxin analogs revealed that an acyl group must be present
on the secondary amine for activity to be observed. However,
when the acetyl or propanoyl functionality was substituted
with a biotin-linked acyl group, indoxin A retained some activity
and selectivity, indicating that larger substituents can be intro-
duced at this site (Figure 6 and Supplemental Data).
To analyze further indoxins’ mechanisms of action, we em-
barked on the development of indoxin affinity probes for protein
target identification. Initially, we synthesized a series of biotin-137
A R T I C L EFigure 5. T55D7 and related analogs enhance doxorubicin lethality
A: RKO-E6 cells were treated with T55D7 and its analogs in the presence or absence of 0.5 mg/ml doxorubicin for 24 hr. Percent inhibition of cell proliferation,
measured with Alamar Blue, is shown in the graph.
B: T55D7 induces S phase arrest in RKO-E6 cells, but not in RKO cells. RKO and RKO-E6 cells were treated with 4 mg/ml T55D7 alone or with 0.5 mg/ml doxorubicin
for 24 hr and stained with propidium iodide; the cell cycle distribution was determined using flow cytometry.
C: A combination dose matrix, showing the combined effect of T55D7 and doxorubicin, in RKO-E6 cells. The experimentally measured cell growth inhibition
(with the Alamar Blue assay) is shown for each concentration. The calculated excess inhibition over the predicted Bliss independence model indicates the
synergy between indoxin B and doxorubicin treatment. The predicted Bliss independence effect was subtracted from the experimentally measured cell
growth inhibition at each pair of concentrations. The color of the squares indicates the level of activity in excess of that predicted by Bliss independence.derivatized indoxin affinity probes I–III (Figures 7 and 8). Biotin
provides a small, high-affinity tag for resin-based target protein
pull-down (Hermanson, 1996). We prepared RKO-E6 cell ly-
sates in a nondenaturing lysis buffer, incubated them with the
indoxin-biotin probes for 12–16 hr at 4ºC, and then passed these
cell lysates over NeutrAvidin beads. The bound proteins were
eluted by boiling NeutrAvidin beads in SDS page buffer;138resolving on Tris-glycine acrylamide gels; and stainingwith Coo-
massie blue, silver, or SYPRO Ruby (Molecular Probes) stains.
However, no selective protein targets were isolated using these
probes. We reasoned that, since indoxins are active at micro-
molar concentrations and have no functional groups that could
form a covalent bond with their protein targets, they provide in-
sufficient affinity for direct target identification.CANCER CELL FEBRUARY 2006
A R T I C L EHowever, we reasoned that incorporation of a photo-activat-
able functionality that allows for covalent bond formation be-
tween a small molecule affinity probe and its target protein
may enhance the likelihood of protein target identification (Dor-
man and Prestwich, 2000; Weber and Beck-Sickinger, 1997).
Benzophenone photoprobes have become the group of choice
for high-efficiency photo-covalent modifications of binding pro-
teins in vitro (Dorman and Prestwich, 1994; Prestwich et al.,
1997), and we suspected they might be useful in cells as well.
We used p-benzoyl-L-phenylalanine (L-Bpa) to incorporate
a benzophenone moiety in the biotin-tagged photoreactive in-
doxin probe IV (Figure 8). We also prepared the biotin-tagged
photoreactive probe V lacking indoxin functionality as a negative
control (Figure 8). The RKO-E6 cell lysates were incubated with
the photoreactive probes and irradiated with 350 nm ultraviolet
light. Proteins crosslinked to these probes were purified using
NeutrAvidin beads and elutedwith SDS buffer. A number of non-
specific bands were observed in both the indoxin probe and
control probe pull-downs (Figure 7D) that may be due to cross-
linking to biotin binding proteins.
We reasoned that biotin-induced crosslinking to the indoxin
photoprobe could be substantially reduced if the biotin affinity
tag were replaced with a nonnatural affinity tag that does not
have high-affinity cellular targets. A number of antibodies have
been developed against fluorescein, providing a convenient
route for the resin-based isolation of protein targets using
fluorescein as an affinity tag. We thus prepared indoxin-benzo-
phenone-fluorescein photoreactive probe VI (Figure 8). Protein
targets crosslinked to these probes were purified by immobiliz-
ing fluorescein on protein A-containing resin with an anti-fluo-
rescein antibody. The proteins were specifically eluted with ex-
cess fluorescein or with low-pH buffer. The fluorescein affinity
tag indeed reduced nonspecific crosslinking to the control
probe VII (Figure 7D). We used this fluoresceinated indoxin
probe for a large-scale protein pull-down using both nuclear
and cytoplasmic fractions of RKO-E6 cell lysates. Purified pro-
teins were sequenced using liquid chromatography/tandem
mass spectrometry (LC-MS/MS). Using the indoxin-fluorescein
photolabel, we identified a number of proteins that had at least
three corresponding peptide sequences in the MS data. In order
to determine which of these proteins are specific for binding in-
doxin, we performed identical experiments for the control probe
VII, lacking indoxin. We found five proteins that were selectively
pulled down with the indoxin probe (Figure 7E) from the nuclear
fraction.
To confirm these findings, we repeated the pull-down with the
indoxin probe and identified two proteins that were again selec-
tively pulled down with indoxin A from the nuclear fraction. The
actin-related proteins myosin 1C and ARP2 were both repeat-
edly pulled down with indoxin probes from the nuclear fraction
but were not present in the control pull-down experiments.
Thus, a nuclear actin-related protein complex involving myosin
1c and ARP2 is a candidate target for mediating the effects of
indoxins.
Discussion
In our cell-based viability screen, we identified several groups
of compounds that potentiate doxorubicin’s lethality in E6-
expressing tumor cells, thus overcoming E6-induced drug resis-
tance. We discovered that the major mechanisms for increasingCANCER CELL FEBRUARY 2006doxorubicin’s lethality in E6-expressing tumor cells are (1) upre-
gulation of topoisomerase IIa and (2) induction of S phase arrest.
Topoisomerase IIa is regulated in proliferation-dependent and
cell cycle-dependent manner (Chow and Ross, 1987; Larsen
and Skladanowski, 1998). The level of topoisomerase IIa in-
creases during S phase and reaches the highest concentration
during late G2/early M phase. In addition, topoisomerase-IIa-
mediated drug sensitivity markedly increases during S phase
(Chow and Ross, 1987). Thus, compounds that induce S phase
arrest should potentiate doxorubicin’s lethality. Moreover, there
is ample evidence that topoisomerase-targeting drug potency is
directly related to the expression levels of the topoisomerases
(Asano et al., 2005; Houlbrook et al., 1996; Kellner et al., 2002;
Koshiyama et al., 2001; MacGrogan et al., 2003). Thus, com-
pounds that directly upregulate topoisomerase levels in tumor
cells should potentiate topoisomerase-targeting drugs.
In this study, we identified a group of compounds (indoxins)
that both upregulate topoisomerase IIa and induce S phase ar-
rest in RKO-E6 cells. Indoxin probes repeatedly and selectively
pulled down myosin 1C from the nuclear fraction of the RKO-E6
cells. The nuclear isoform of myosin 1C (NMI) shares more than
98% sequence homology with cytoplasmic myosin 1C (Pestic-
Dragovich et al., 2000). Although LC-MS/MS analysis of the iso-
lated sequences is not sufficient for distinguishing between the
nuclear and cytoplasmic myosin 1C, the protein was isolated
from the nuclear fraction of RKO-E6 cells and presumably is
the nuclear isoform.
Given that indoxins upregulate topoisomerase IIa in both RKO
and RKO-E6 cells but only cause S phase arrest in RKO-E6
cells, these two mechanisms can be dissociated. We believe,
therefore, that indoxins are dual-action compounds that cause
these two distinct effects (topoisomerase IIa upregulation and
S phase arrest) and that they both contribute to increased doxo-
rubicin sensitivity. The Bliss independence analysis supports
this dual-mechanism hypothesis by demonstrating that indoxins
showed greater combination effect with doxorubicin in RKO-E6
cells than in RKO or HeLa cells. The ability of indoxins to inhibit
nuclear myosin 1C could mediate topoisomerase IIa transcrip-
tional upregulation, as nuclear myosin 1C has been linked to
transcriptional control (see below). A cytosolic myosin target
might mediate the S phase-arresting activity of indoxins. Both
activities should contribute to the increased sensitivity of in-
doxin-treated cells to doxorubicin.
Nuclear myosin 1C colocalizes with RNA polymerase II and
may affect transcription (Pestic-Dragovich et al., 2000). Nuclear
actin and myosin 1C (NMI) are associated with rDNA and are re-
quired for RNA polymerase I transcription (Pestic-Dragovich
et al., 2000). Depletion or inhibition of nuclear myosin 1C or actin
results in decreased nucleolar transcription, while overexpres-
sion of NMI amplifies pre-rRNA synthesis (Pestic-Dragovich
et al., 2000). Thus, there is ample precedent for our hypothesis
that nuclearmyosin 1c could regulate topoisomerase IIa expres-
sion.
In summary, we have found that the most tractable mecha-
nism for overcoming doxorubicin resistance is upregulation of
the direct target of doxorubicin, topoisomerase IIa. In addition,
induction of S phase arrest potentiates the cytotoxicity of topo-
isomerase IIa-mediated DNA damage. Each of these mecha-
nisms provides modest potentiation of doxorubicin’s lethality.
For example, cotreatment of RKO-E6 cells with hydroxyurea
(a compound that arrests cells in S phase) and doxorubicin139
A R T I C L EFigure 6. Indoxins enhance doxorubicin lethality
A: Chemical structures of indoxin A and indoxin B.
B: Indoxin-B-treated RKO and RKO-E6 cells in the presence of 0.5 mg/ml doxorubicin or 0.2 mg/ml podophyllotoxin. RKO and RKO-E6 cells were treated in
384-well plates for 24 hr. Percent inhibition of cell proliferation, measured with Alamar Blue, is shown in the graph.
C: RKO-E6 cells were treated with 0.5 mg/ml doxorubicin, 4 mg/ml indoxin A, or 4 mg/ml indoxin B for 24 hr, and the level of topoisomerase IIawas determined by
Western blot. The membrane was reprobed for eIF4E as a loading control.
D: RKO, RKO-E6, or HeLa cells were treated with 4 mg/ml of indoxin A alone and/or with 0.5 mg/ml doxorubicin for 24 hr. Cells were stained with propidium iodide,
and the cell cycle distribution was determined using flow cytometry.140 CANCER CELL FEBRUARY 2006
A R T I C L EE: A combination dose matrix, showing the combined effect of indoxin B and doxorubicin in RKO-E6 cells. The experimentally measured cell growth inhibition
(Alamar Blue assay) is shown for each concentration. The calculated excess inhibition over the predicted Bliss independence model indicates the synergy
between indoxin B and doxorubicin treatment. The predicted Bliss independence effect was subtracted from the experimentally measured cell growth in-
hibition at each pair of concentrations. The color of the squares indicates the level of the synergy.
Figure 7. Indoxin affinity probes
A: Structures of indoxin-biotin labels.
B: Structures of indoxin-benzophenone-biotin labels.
C: Structures of indoxin-benzophenone-fluorescein labels.
D: Proteins isolated using indoxin and control probes; nonspecific crosslinking was observed using the benzophenone-biotin control probe. Replacement of
biotin with fluorescein as an affinity tag reduced nonspecific crosslinking.
E: Proteins that were selectively isolated using the indoxin-benzophenone-fluorescein probe, but not the control benzophenone-fluorescein probe. Myosin 1C
and ARP2 were repeatedly identified in this manner.CANCER CELL FEBRUARY 2006 141
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A R T I C L Eresulted in only modest upregulation of doxorubicin’s lethality
(data not shown). However, compounds that drive both of these
mechanisms result in a strong sensitization effect.
Experimental procedures
Cell lines
RKO colon carcinoma cells (ATCC, order #CRL-2577) and RKO-E6 colon
carcinoma cells transfected with HPV E6 inserted in pCMV.3 (ATCC, order
#CRL-2578) were grown in MEM with 2 mM L-glutamine and Earle’s BBS
adjusted to contain 1.5 g/l NaHCO3, 0.1 mM nonessential amino acids,
and 1.0 mM sodium pyruvate and supplemented with 10% fetal bovine
serum, penicillin, and streptomycin (pen/strep). Both cell lines were incu-
bated at 37ºC in a humidified incubator containing 5% CO2.
Compound libraries
Our ACL comprising 2214 compounds, the NINDS library of 1040 com-
pounds obtained from the National Institute of Neurological Disorders and
Stroke, and our TIC library comprised of 12,960 synthetic compounds
(Chembridge) and 10,725 natural products and their analogs (IBS and Tim-
Tec) were used in the primary screen. All compound libraries were prepared
as 4mg/ml solutions in DMSO in 384-well polypropylene plates and stored at
220ºC.
Benzalkonium chloride (cat. #234427, MW), benzethonium chloride (cat.
#B-8879, MW448.1), D-biotin (cat. #B-4501,MW244.3), S-(+)-camptothecin
(cat. #C9911, 348.4), cetyltrimethylammonium bromide (cat. #855820, MW
364.46), cycloheximide (C-76798, MW 281.4), doxorubicin (cat. #D-1515,
MW 580.0), hexadecylpyridinium chloride monohydrate (cat. #C9002, MW
358.01), hydroxyurea (cat. #H-8627, MW 76.05), and podophyllotoxin (cat.
#P-4405, MW 414.4) were obtained from Sigma-Aldrich. Indoxin A (MW
415.61) and indoxin B (MW 423.59) were obtained from Interbioscreen Ltd.
Compound designation
Each hit compound from the primary screen was assigned a designation
based on the location of this compound in the libraries. For example, the des-
ignation T86N7 indicates that compound is located on the TIC library’s
mother plate number 86, row N, column 7.
Screening
Daughter replica plates were prepared with a Zymark Sciclone ALH by dilut-
ing DMSO stock plates 50-fold in medium lacking serum and penicillin/strep-
tomycin to obtain a compound concentration in daughter plates of 80 mg/ml
with 2%DMSO. Assay plates were prepared by seeding cells in black, clear-
bottom 384-well pates (Corning Inc., cat. #3712). Columns 3–22 were treated
with compounds from a daughter library plate by transferring 3 ml from the
daughter library plate using 384-position fixed cannula array. The final com-
pound concentrations in assay plates were 4 mg/ml.
Primary screen: Alamar Blue viability assay
The Alamar Blue assay incorporates a fluorimetric/colorimetric growth indi-
cator that changes color in the response to chemical reduction by viable cells
(Nociari et al., 1998). Cells were seeded at a density of 3000 cells (57 ml) per
well in 384-well black, clear-bottom plates using a syringe bulk dispenser
(Zymark Sciclone ALH). Three microliters were removed from a compound
daughter plate using a 384 fixed cannula head and added to the assay plate,
making the final concentration of each compound 4 mg/ml. The plates were
incubated for 24 hr at 37ºC. Ten microliters of 40% Alamar Blue (Biosource
Int., cat. #DAL1100) solution in media was added to each well (1:10 dilution).
The assay plates were incubated for 16 hr. Fluorescence intensity was deter-
mined using a Packard Fusion platereader with a 535 nm excitation filter and
a 590 nm emission filter. The average fluorescence for the whole plate was
used as a positive control. Average percentage inhibition for each well was
determined using our freely available SLIMS software (Kelley et al., 2004).CANCER CELL FEBRUARY 2006Retesting of compounds in a dilution series
The daughter plates for the 2-fold dilution serieswere preparedwith a Zymark
Sciclone ALH by diluting the replica daughter plates to obtain compound
concentrations from 8 mg/ml–0.008 mg/ml (columns 8–18). Columns 1–7
were used as untreated control. RKO-E6 cells were seeded at the density
of 3000 per well in 55 ml, and 5 ml was added from the daughter plate. RKO
cells were seeded at the density of 2000 per well in 55 ml, and 5 ml were added
from the daughter plate. The assay was incubated for 24 hr at 37ºC. Ten per-
cent Alamar Blue was added to each well, and the assay was incubated for
16 hr (see above).
Compounds for retesting were purchased from the manufacturers or from
Sigma-Aldrich (see above). Stocks were prepared in DMSO at 4 mg/ml.
Bliss independence analysis
Each cell line (RKO, RKO-E6, HeLa, and TC32) was treated with a dose com-
bination matrix of doxorubicin and a selected hit compound. Each treatment
was done in a triplicate in 384-well format. The average percent inhibition of
cell proliferation, measured with Alamar Blue, was determined using the fol-
lowing formula:
Percent inhibition= ð12 ðX2NÞ=ðP2NÞÞ
X, the average fluorescence readout for each treatment; N, the negative
control signal (in the absence of any cells); P, the positive control (the average
fluorescence readout of untreated cells).
The predicted Bliss additive effect was determined using the following for-
mula:
C=A +B2A*B
C, the combined response for two single compounds with effects A and B;
A, the percent inhibition of compoundA at the particular concentration; B, the
percent inhibition of compound B at the particular concentration.
The excess over predicted Bliss independence was calculated by sub-
tracting the predicted Bliss effect for each treatment from the experimentally
determined percent inhibition for the same treatment.
Western blot analysis
Antibodies were obtained from the indicated suppliers: p53 (Oncogene/Cal-
biochem, cat. #OP43), p21 (Santa Cruz Biotechnology Inc., cat. #sc-817),
MDM2 (Santa Cruz Biotechnology Inc., cat. #sc-965), topoisomerase IIa
(TopoGEN, cat. #2011-1), topoisomerase I (BD PharMingen, cat. #556597),
Cyclin B (BD Transduction Laboratories, cat. #610219), Cyclin A (BD Trans-
duction Laboratories, cat. #611268), anti-fluorescein-HRP (Molecular
Probes, cat. #A21253), anti-biotin-HRP (Cell Signaling Technology, cat.
#7075; Jackson ImmunoResearch Laboratories, cat. #200-032-096), eIF4E
(Santa Cruz Biotechnology Inc., cat. #sc-9976 HRP).
Cells were lysed in denaturing lysis buffer (50 mM HEPES KOH [pH 7.4],
40 mM NaCl, 2 mM EDTA, 1.5 mM Na3VO4, 50 mM NaF, 10 mM sodium
pyrophosphate, 10 mM sodium b-glycerophosphate, 0.5% Triton X-100,
and protease inhibitor tablet [Roche, cat. #11777700]). Protein content was
quantified using a Bio-Rad protein assay reagent (Bio-Rad, cat. #500-
0006). Equal amounts of protein were resolved on SDS-polyacrylamide
gels. Proteins were transferred onto a PVDF membrane, blocked with 5%
milk, and incubated with the appropriate primary and secondary antibodies.
The membranes were developed with chemiluminescence reagent (5 ml of
100 mM TRIS buffer [pH 8.5] and 5 ml of 30% H2O2 were mixed with 10 ml
of 100 mM TRIS buffer [pH 8.5], 11 ml of 90 mM p-coumaric acid, and 25 ml
of 250 mM luminol and immediately added to the PVDF membrane for
1 min). To test for equivalent loading in each lane, blots were stripped,
blocked, and probed with an anti-eIF-4E antibody.
Flow cytometry
RKO, RKO-E6, or HeLa cells were seeded in 20 cm dishes in 10 ml of growth
medium. Cells were allowed to adhere and then treated with the selected
compounds for 24 hr. The treated cells were collected, washed 23 withFigure 8. Synthesis of indoxin affinity probes
Synthesis of indoxin probes. Abbreviations: Boc, t-butoxycarbonyl; CDI, N,N0-carbonyldiimidazole; DIPEA, diisopropylethylamine; DMF, dimethylformamide;
DMSO, dimethyl sulfoxide; Fmoc, 9-fluorenylmethoxycarbonyl; HBTU,O-benzotriazol-1-yl-N,N,N0,N0-tetramethyluronium hexafluorophosphate; PFP, pentafluor-
ophenol; TFA, trifluoroacetic adic; TFP, tetrafluorophenol.143
A R T I C L EPBS, and counted. The cell pellet was resuspended in 500 ml of ice-cold PBS,
and 2–5 ml of cold 70% ethanol (220ºC) was added. Cells were fixed for 1 hr
or overnight at 4ºC. Five to ten million cells were placed into a 15 ml conical
tube and centrifuged at 1000 g. Cells were washed 23 with 1% calf serum
in PBS. Cells were resuspended in 800 ml of 1% calf serum in PBS, and
100 ml of RNase (1 mg/ml) and 100 ml of propidium iodide (400 mg/ml) were
added. Cells were incubated at 37ºC for 30 min and then analyzed by flow
cytometry.
Synthesis of affinity probes
Solvents were purchased from Aldrich and used without further purification.
Common synthetic reagents were obtained from commercial sources and
usedwithout further purification. Structures are shown in Figure 8 (see legend
for abbreviations).
Indoxin derivative I
T13M7 (10mg, 1 eq.) was dissolved inmethylene chloride and added to PFP-
biotin (12 mg, 1 eq., Pierce, cat. #21218) solution in DMF. The reaction was
stirred for 1 hr at RT and for 30min at 40ºC. A yield of >95%was confirmed by
LC-MS. Solvents and pentafluorophenol were removed under high vacuum,
and the crude product was used without further purification.
Indoxin derivative II
BOC-6-aminohexanoic acid (36 mg, 1.1 eq.) was dissolved in chloroform,
and CDI (27 mg, 1.2 eq.) was added to the reaction solution. The reaction
mixture was stirred at RT for 30 min, and then T13M7 (50 mg, 1 eq.) was
added to the reaction. The coupling reaction proceeded slowly and required
heating at 50ºC and addition of one more equivalent of CDI. The BOC-pro-
tecting group was removed with 30% TFA/70%CH2Cl2 at RT for 30 min. Sol-
vents and TFAwere removed under high vacuum, and the crude product was
extracted with CHCl3/5% K2CO3 solution. Organic phase was separated,
washed with dH2O twice, and dried under vacuum to provide the product
in Figure 8A. The product (12 mg, 1 eq.) was dissolved in chloroform and
added to the PFP-biotin (7 mg, 1 eq.) solution in DMSO, followed by DIPEA
(20 ml). The reaction was stirred at RT for 30 min. LC-MS analysis confirmed
complete coupling. Chloroform, DIPEA, and pentafluorophenol were re-
moved under high vacuum, and the crude product was used without further
purification.
Indoxin derivative III
T13M7 (2.3 mg, 1 eq.) was dissolved in chloroform and added to TFP-PEO-
biotin (4.7 mg, 1 eq., Pierce, cat. #21219) solution in chloroform. The reaction
was stirred for 1 hr at RT. LC-MS analysis indicated complete consumption of
TFP-PEO-biotin, w75% of product, and w25% of T13M7 excess. The sol-
vent and tetrafluorophenol were removed under high vacuum; the crude
product was triturated with ethyl ether to remove the excess of T13M7 and
dried under vacuum. The product was used without further purification.
Benzophenone-biotin V
N-(+)-Biotinyl-6-aminohexanoic acid (239 mg) and 4-benzoyl-L-phenyla-
lanyl-6-aminoxehanoic acid methyl ester (237 mg) were dissolved in DMF,
and 230 ml of DIPEA was added to the reaction mixture, followed by
237 mg of HBTU. The reaction mixture was stirred at RT for 30 min.
LC-MS analysis showed complete reaction. The solvent and excess of DI-
PEA were removed under high vacuum. The crude product was dissolved
in CHCl3 and extracted 23 with 1% HCl. Organic phase was separated, sol-
vent was removed, and the product was purified using rotary chromatogra-
phy (SiO2 solid phase). Yield 325 mg (73.4%).
Indoxin-benzophenone-biotin IV
1. Compound V (100 mg) was dissolved in aqueous methanol, 1 eq. of LiOH
was added to the reaction mixture, and the reaction was refluxed overnight.
LC-MS analysis confirmed quantitative hydrolysis of the methyl ester. The
crude product was dissolved in CHCl3 and extracted with 1% HCl and
dH2O. Organic phase was separated and dried over anhydrous Na2SO4 for
1 hr. Then, Na2SO4 was filtered off, and solvents were removed under vac-
uum to provide pure product in a quantitative yield.
2. N-[N-(+)-Biotinyl-6-aminohexanoyl]-4-benzoyl-L-phenylalanyl-6-amino-
xehanoic acid (Figure 8C) was dissolved in CHCl3, and 1.1 eq. of CDI was
added to the reaction mixture. The reaction was stirred at RT for 30 min,
and then T13M7 was added to the reaction. The reaction was stirred at RT
for 1 hr and at 50ºC for 30min. LC-MS analysis confirmed complete coupling.
The solution of the crude product in CHCl3 was extracted with 0.1% HCl and
dH2O. The organic phase was separated and dried over anhydrous Na2SO4
for 1 hr. Then, Na2SO4 was filtered off, and solvents were removed under144vacuum to provide more than 90% pure product: indoxin-benzophenone-
biotin VI.
Benzophenone-fluorescein VII
1. BOC-6-aminohexanoic acid (105 mg) was dissolved in w5 ml of CHCl3,
and 1.1 eq. of CDI (74 mg) was added to the reaction. The reaction mixture
was stirred under argon at RT for 30 min. Then, 180 mg of 4-benzoyl-L-
phenylalanyl-6-aminoxehanoic acid methyl ester (Figure 8B) was added to
the reaction, and the reaction mixture was stirred at RT for 2 hr. LC-MS anal-
ysis indicated complete coupling. The crude product solution in CHCl3 was
extracted twice with H2O (pHw3) and once with dH2O to remove imidazole.
The organic phase was separated, and the solvent was removed under
vacuum. The oily product was dissolved in 3 ml of CH2Cl2, and 1 ml of TFA
was added to the reaction. The reaction mixture was stirred at RT for 30
min. LC-MS and TLC analysis indicated complete removal of BOC-protect-
ing group, which provided quantitative yield of the compound in Figure 8D.
2. Fifty milligrams of the compound in Figure 8D was dissolved inw1 ml of
DMF and added to the solution of 5-(and-6)-carboxyfluorescein succinimidyl
ester (46.5 mg) in DMF. The reaction mixture was stirred at RT for 2 hr and
heated at 50ºC for 15 min. Solvents were removed, and the crude product
was used for the next step without further purification: the crude product
was dissolved in CH3OH/H2O (1:1), and LiOHwas added to the reaction mix-
ture till pH 11. The reaction was refluxed for 1 hr. LC-MS analysis indicated
complete hydrolysis of methyl ester. Then, solvents were removed under
vacuum, and the crude product was dissolved in CHCl3/EtOH and extracted
with acidic water (pH = 1). The organic phase was separated, and the crude
product was purified using rotary TLC (SiO2 solid phase) to provide benzo-
phenone-fluorescein VII.
Indoxin-benzophenone-fluorescein VI
Benzophenone-fluorescein probe VII (6.8mg) and T13M7 (2.86mg) were dis-
solved in 1 ml of DMF. DIPEA and HBTU (2.8 mg) were added to the reaction
mixture, and the reaction mixture was stirred at RT for 30 min. LC-MS anal-
ysis indicated onlyw50% coupling; therefore, another 2.8 mg of HBTU was
added, and the reaction mixture was heated at 50ºC for 10 min. LC-MS anal-
ysis confirmed more than 90% coupling reaction. DMF was removed under
high vacuum to provide crude product. The oily residue was triturated with
Et2O to remove excess of T13M7, DIPEA, and HBTU byproducts. Then,
the product—indoxin-benzophenone-fluorescein VI—was used without fur-
ther purification.
Affinity purification of protein targets
Biotinylated indoxin probes
RKO-E6 cells were lysed in the nondenaturing lysis buffer (1% NP-40,
50 mM Tris$HCl, pH 7.4, 300 mM NaCl, 5 mM EDTA, 0.02% sodium azide,
10 mM iodoacetamide, 1 mM PMSF, and protease inhibitor tablet [Roche,
cat. #11777700]). The cell lysates were precleared with Immobilized Neutr-
Avidin gel (Pierce Biotechnology, cat. #29200) for 1 hr at 4ºC. Then, the cell
lysates were incubated with the small molecule affinity probes for 10–12 hr
at 4ºC. NeutrAvidin beads were added to the cell lysates and incubated with
the indoxin probes I, II, and III composed of an indoxin moiety, a linker, and
biotin. The beads were incubated at 4ºC for 1 hr. Then, the NeutrAvidin
beads were separated from the cell lysates and washed twice with the non-
denaturing lysis buffer and twice with PBS (for 1D analysis) or with dH2O (for
2D analysis). The samples for 1D analysis were boiled in SDS page buffer
and resolved using Tris-Glycine precast gels. Proteins were detected with
Coomassie blue or silver stain. The samples for 2D analysis were sonicated
in ZOOM 2D Protein Solubilizer 1 (Invitrogen, cat. #ZS10001) and resolved
following the protocol provided by Invitrogen. The cell lysates with the pho-
toreactive probes IV and V were placed in the optical glass cells (Starna, cat.
#1-SOG-10-GL14-S), purged with argon gas for 5 min, and irradiated at
350 nm for 15 min in Rayonet Reactor. The crosslinked proteins were iso-
lated and resolved as described above. Western blot analysis was done
using anti-biotin antibody.
Fluoresceinylated indoxin probes
The above described protocol was used to isolate proteins crosslinked to
photoreactive probes VI and VII using total cell lysates. The nuclear and cy-
tosolic fractions were separated following the published protocol (Lee et al.,
1988; Lee and Green, 1990), except the cytoplasmic and the nuclear frac-
tions were used for the affinity purification without dialysis. The affinity puri-
fication was done as described above, except that protein A beads and anti-
fluorescein antibody were used for the pull-down of crosslinked proteins.CANCER CELL FEBRUARY 2006
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The Supplemental Data include five supplemental figures, two supplemental
Excel files, a zip file containing four SDF files, and a text file explaining the
fields in the SDF files. The Supplemental Data can be found with this article
online at http://www.cancercell.org/cgi/content/full/9/2/133/DC1/.
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